Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lisata Therapeutics, Inc. - Common Stock (NQ: LSTA ) 3.160 UNCHANGED Streaming Delayed Price Updated: 3:59 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Lisata Therapeutics, Inc. - Common Stock < Previous 1 2 3 Next > Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update February 29, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Earnings Scheduled For February 29, 2024 February 29, 2024 Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. Via Benzinga Lisata Therapeutics's Earnings Outlook February 28, 2024 Via Benzinga Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time February 22, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Present at BIO CEO & Investor Conference February 20, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Earnings Preview: Lisata Therapeutics November 01, 2023 Via Benzinga Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme January 17, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy January 04, 2024 LSTA1, the Company’s lead investigational product, in combination with standard-of-care therapy, potentiated a complete response in a patient with metastatic gastroesophageal adenocarcinoma From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma December 12, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Present at NobleCon19 Investor Conference November 28, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Participation in Upcoming Conferences in November November 09, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update November 02, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time October 26, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide October 24, 2023 Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standard-of-care versus standard-of-care alone in subjects with advanced solid tumors... From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer October 17, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Participation in Upcoming Conferences in October September 28, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Participation in InfoSec World 2023 September 20, 2023 Gregory Berkin, Chief Information Officer of Lisata, to participate in keynote discussion on CISO leadership and managing the risks of artificial intelligence From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors September 12, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma September 06, 2023 Independent Data Safety Monitoring Committee recommends study continuation (criteria for futility not met) From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Participation in Upcoming Conferences in September September 05, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update August 14, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Earnings Scheduled For August 14, 2023 August 14, 2023 Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million. Via Benzinga Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma August 08, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time August 07, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors July 11, 2023 Lasker Prize winning researcher and serial entrepreneur will remain an advisor to the Company From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference June 12, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1 May 24, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update May 09, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Host First Quarter 2023 Financial Results Conference Call on Tuesday, May 9th, at 4:30 p.m. Eastern Time May 02, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Participation in Upcoming Conferences in May April 27, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
